Group
Anti-idiotype vaccine mAb
Group Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Mechanism of Action | Anti-idiotype vaccine |
| Drugs in group | Racotumomab |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
No direct RT-interaction data; theoretical immunologic potentiation (RT-induced ICD/antigen release priming vaccine response) (Lu and Deng, Journal of Clinical Investigation, 2026; Yahia et al., Molecular Carcinogenesis, 2026). No DNA-level sensitization; any theoretical risk would be immune-mediated.
The data above refer to patients treated with Anti-idiotype vaccine mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.